In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Assertio Therapeutics (ASRT – Research Report), with a price target of $3.00. The company’s shares closed ...
Short interest in Assertio Holdings Inc (NASDAQ:ASRT) decreased during the last reporting period, falling from 6.04M to 5.73M. This put 6.07% of the company's publicly available shares short.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback